Genetic polymorphisms and treatment response in advanced non-small cell lung cancer

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

“…31,32 Moreover, the potential value of SNPs as predictive markers has been highlighted in various cancer types, including pancreas, 33 esophagus 34 and lung tumors. 35 In this study, we showed that the SOD2 rs4880 and IL13 rs1800925 polymorphims are independent predictive markers of the response to preoperative RT-CT in rectal cancer. Such markers may help discriminating rectal cancer patients who might benefit from neoadjuvant RT-CT from those who should be candidates for alternative treatments such as targeted therapy (for example, anti-epidermal growth factor receptor or anti-vascular endothelial growth factor).…”

Recent Candidate Molecular Markers: Vitamin D Signaling and Apoptosis Specific Regulator of p53 (ASPP) in Breast Cancer

“…Moreover, gene knockdown of iASPP in different cancer cell lines (Liu et al, 2009;Chen et al, 2010;Liu et al, 2011;Zhang et al, 2011) with mutant/ defective p53 or wild type p53 by using RNAi resulted into reduced mRNA and protein expression of iASPP and led to cell growth deceleration and induction of apoptosis, suggestive of additional functions of this oncoprotein in p53-independent manner. Furthermore, genetic polymorphisms at both TP53BP2 and iASPP have also been reported (Ju et al, 2005;Su et al, 2007) in gastric and non-small cell lung cancer respectively. Significant association was found between gastric cancer and different single nucleotide polymorphisms in TP53BP2 gene (g.206692C>T, g.198267A>T, g.164895G>A and g.152389A>T), whereas A allele of iASPP (A67T) was linked to treatment response to combined chemotherapy and radiotherapy in non-small lung cell carcinoma.…”

ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy

“…Since Yu et al, reported that ERCC1 mRNA levels were reduced in human ovarian cancer cells with a variant allele, and that those cells were inferior in recovery from platinum damage to cells with wild-type allele (21), several studies have assessed the relation between ERCC1 codon 118 polymorphism and sensitivity to a platinum agent in ovarian cancers, colorectal cancers, gastric cancers, and non-small cell lung cancers (22)(23)(24)(25)(26)(27)(28)(29)(30)(31). It is possible for ERCC1 codon 118 polymorphism to be a biomarker for assessing the sensitivity to a platinum-based therapy, although it is still a matter of controversy whether either a wild-type allele or a mutant-type allele affect the platinum resistance.…”